Oaktree Acquisition III Life Sciences, a blank check company formed by Oaktree Capital targeting healthcare businesses, filed on Friday with the SEC to raise up to $175 million in an initial public offering. The company is led by Chairman John Frank, Vice Chairman of Oaktree Capital, and CEO Zaid Pardesi, Managing Director of Oaktree’s private debt strategy. The executives led previous Oaktree-founded SPACs, including Oaktree Acquisition, which completed a business combination with Hims & Hers Health (Nasdaq: HIMS) in 2021, Oaktree Acquisition II, which completed a business combination with Alvotech (Nasdaq: ALVO) in 2022, and Oaktree Acquisition III, which withdrew its $325 million acquisition in 2023.
Read the full article: SPAC Oaktree Acquisition III Life Sciences Files for a $175M IPO, Formed by Oaktree Capital Management //
Source: https://www.renaissancecapital.com/IPO-Center/News/107084/SPAC-Oaktree-Acquisition-III-Life-Sciences-files-for-a-$175-million-IPO-for